Prognostic relevance of DHAP dose-density in relapsed Hodgkin
lymphoma: an analysis of the German Hodgkin-Study Group

J 2016

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

SASSE, Stephanie, Magdalena ALRAM, Horst MÜLLER, Lenka ŠMARDOVÁ, Bernd METZNER et. al.

Základní údaje

Originální název

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

Autoři

SASSE, Stephanie (276 Německo), Magdalena ALRAM (276 Německo), Horst MÜLLER (276 Německo), Lenka ŠMARDOVÁ (203 Česká republika, garant, domácí), Bernd METZNER (276 Německo), Hartmut DOEHNER (276 Německo), Thomas FISCHER (276 Německo), Dietger W. NIEDERWIESER (276 Německo), Norbert SCHMITZ (276 Německo), Kerstin SCHÄFER-ECKART (276 Německo), John M. M. RAEMAEKERS (528 Nizozemské království), Oliver SCHMALZ (276 Německo), Bastian V. TRESCKOW (276 Německo), Andreas ENGERT (276 Německo) a Peter BORCHMANN (276 Německo)

Vydání

Leukemia & Lymphoma, Abingdon, Taylor & Francis LTD, 2016, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.755

Kód RIV

RIV/00216224:14110/16:00089247

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3109/10428194.2015.1083561

UT WoS

000375027000014

Klíčová slova anglicky

DHAP; dose density; hematotoxicity; outcome; relapsed Hodgkin lymphoma

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 7. 2016 15:10, Soňa Böhmová

Anotace

V originále

Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.

Citovat

SASSE, Stephanie, Magdalena ALRAM, Horst MÜLLER, Lenka ŠMARDOVÁ, Bernd METZNER, Hartmut DOEHNER, Thomas FISCHER, Dietger W. NIEDERWIESER, Norbert SCHMITZ, Kerstin SCHÄFER-ECKART, John M. M. RAEMAEKERS, Oliver SCHMALZ, Bastian V. TRESCKOW, Andreas ENGERT a Peter BORCHMANN. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leukemia & Lymphoma. Abingdon: Taylor & Francis LTD, 2016, roč. 57, č. 5, s. 1067-1073. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2015.1083561.

@article{1323300,
   author = {Sasse, Stephanie and Alram, Magdalena and Müller, Horst and Šmardová, Lenka and Metzner, Bernd and Doehner, Hartmut and Fischer, Thomas and Niederwieser, Dietger W. and Schmitz, Norbert and SchäferandEckart, Kerstin and Raemaekers, John M. M. and Schmalz, Oliver and Tresckow, Bastian V. and Engert, Andreas and Borchmann, Peter},
   article_location = {Abingdon},
   article_number = {5},
   doi = {http://dx.doi.org/10.3109/10428194.2015.1083561},
   keywords = {DHAP; dose density; hematotoxicity; outcome; relapsed Hodgkin lymphoma},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & Lymphoma},
   title = {Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group},
   volume = {57},
   year = {2016}
}

TY  - JOUR
ID  - 1323300
AU  - Sasse, Stephanie - Alram, Magdalena - Müller, Horst - Šmardová, Lenka - Metzner, Bernd - Doehner, Hartmut - Fischer, Thomas - Niederwieser, Dietger W. - Schmitz, Norbert - Schäfer-Eckart, Kerstin - Raemaekers, John M. M. - Schmalz, Oliver - Tresckow, Bastian V. - Engert, Andreas - Borchmann, Peter
PY  - 2016
TI  - Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group
JF  - Leukemia & Lymphoma
VL  - 57
IS  - 5
SP  - 1067-1073
EP  - 1067-1073
PB  - Taylor & Francis LTD
SN  - 10428194
KW  - DHAP
KW  - dose density
KW  - hematotoxicity
KW  - outcome
KW  - relapsed Hodgkin lymphoma
N2  - Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.
ER  -

SASSE, Stephanie, Magdalena ALRAM, Horst MÜLLER, Lenka ŠMARDOVÁ, Bernd METZNER, Hartmut DOEHNER, Thomas FISCHER, Dietger W. NIEDERWIESER, Norbert SCHMITZ, Kerstin SCHÄFER-ECKART, John M. M. RAEMAEKERS, Oliver SCHMALZ, Bastian V. TRESCKOW, Andreas ENGERT a Peter BORCHMANN. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. \textit{Leukemia \&{} Lymphoma}. Abingdon: Taylor \&{} Francis LTD, 2016, roč.~57, č.~5, s.~1067-1073. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2015.1083561.

Podrobný výpis o publikaci